Furthermore, TFDP3 was increased in the minimal residual disease (MRD)-positive childhood T-ALL patients, and the silencing of TFDP3 expression can benefit in overcoming chemoresistance after chemical treatment (25). Here, TFDP3 is linked to acute lymphoblastic leukemia.